Curcumin ZnO and MgO Nanoparticles Confer Protective Effects against Ketamine-Induced Bipolar in Mice: Role of Brain-Derived Neurotrophic Factor

Background: Bipolar disorder (BD), or bipolar disease, is a prevalent psychiatric condition. Current treatment options are often ineffective, with numerous side effects. Brain-Derived Neurotrophic Factor (BDNF) may be a potential biomarker for bipolar disorder. Methods: Synthesized Cur-ZnO NPs (curcumin conjugated ZnO nanoparticles) and Cur-MgO NPs (curcumin conjugated MgO nanoparticles) were characterized by FTIR (Fourier transform infrared), FE-SEM (Field emission scanning electron microscopy), EDX (energy dispersive X-ray analysis), and UV (Ultraviolet)-vis spectrophotometry. Behavioral changes in an Open Field Test and the level of hippocampal BDNF were evaluated in a ketamine-induced manic-depressive-like behavior mouse model. Mice were treated ip daily for ۱۴ days. Control mice received saline; positive control mice received ۲۵ mg/kg ketamine, ketamine (۲۵ mg/kg) and lithium (۴۵ mg/kg), ۵ mg/kg MgO (Magnesium oxide), ۵ mg/kg ZnO (Zinc oxide) and ketamine (۲۵ mg/kg), or ۴۰ mg/kg curcumin and ۲۵ mg/kg ketamine. Mice in the treatment group were given ketamine (۲۵ mg/kg) plus Cur-MgO NPs or Cur-ZnO NPs (۱۰, ۲۰, or ۴۰ mg/kg). Results: Both nanoparticles were chemically characterized. Both nanoparticles increased central square entries, time spent in the center zone, the rearing frequency, and ambulation distance in the ketamine treated mice in the OFT. The hippocampal BDNF levels were also increased compared to the ketamine-treated mice. Conclusion: Cur-ZnO NPs and Cur-MgO NPs may be potential candidates for treating manic-depressive-like disorders.

کلیدواژه ها:

Nanoparticle ، Bipolar Disorder ، Brain-Derived Neurotrophic Factor ، Open Field Test